Valuation: Genmab

Market Cap 106B 16.12B 14.11B 13.03B 12.15B 22.9B 1,524B 23.3B 156B 60.66B 752B 60.57B 59.22B 2,621B P/E 2026 *
22.5x
P/E 2027 * 15.8x
Enterprise Value 125B 19.11B 16.72B 15.44B 14.4B 27.13B 1,806B 27.62B 185B 71.89B 891B 71.78B 70.18B 3,105B EV / Sales 2026 *
4.51x
EV / Sales 2027 * 3.64x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
+47.49%+4.14% - - 16.12B
+3.31%-0.20%+72.71%+128.31% 55.78B
-1.32%+16.55%+89.14%+101.41% 55.66B
-0.88%+3.05%-12.29%-13.48% 23.84B
+1.79%+4.76%+6.33%+407.18% 22.7B
+0.33%+6.10%+23.58%+185.03% 13.64B
+5.51%+22.37%+171.85%+333.54% 14.8B
+2.58%+5.25%+78.57%+133.94% 12.16B
-2.22%+6.62%+158.20%+161.53% 11.85B
+2.81%+3.57%+423.73%+132.05% 11.34B
Average +1.15%+5.52%+112.43%+174.39% 24.64B
Weighted average by Cap. +1.04%+4.76%+87.33%+154.32%

Financials

2026 *2027 *
Net sales 27.73B 4.24B 3.71B 3.42B 3.19B 6.02B 401B 6.12B 41.06B 15.94B 198B 15.92B 15.56B 689B 32.45B 4.96B 4.34B 4.01B 3.74B 7.04B 469B 7.17B 48.06B 18.66B 231B 18.63B 18.22B 806B
Net income 4.76B 728M 637M 588M 548M 1.03B 68.8B 1.05B 7.05B 2.74B 33.95B 2.73B 2.67B 118B 7.03B 1.07B 940M 868M 810M 1.53B 102B 1.55B 10.41B 4.04B 50.12B 4.04B 3.95B 175B
Net Debt 19.52B 2.98B 2.61B 2.41B 2.25B 4.24B 282B 4.31B 28.91B 11.22B 139B 11.21B 10.96B 485B 12.49B 1.91B 1.67B 1.54B 1.44B 2.71B 180B 2.76B 18.49B 7.18B 89.03B 7.17B 7.01B 310B
Logo Genmab
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A